IL118836D0 - Pharmaceutical compositions comprising S-(-)N-propargyl-1-aminoindan - Google Patents

Pharmaceutical compositions comprising S-(-)N-propargyl-1-aminoindan

Info

Publication number
IL118836D0
IL118836D0 IL11883696A IL11883696A IL118836D0 IL 118836 D0 IL118836 D0 IL 118836D0 IL 11883696 A IL11883696 A IL 11883696A IL 11883696 A IL11883696 A IL 11883696A IL 118836 D0 IL118836 D0 IL 118836D0
Authority
IL
Israel
Prior art keywords
aminoindan
propargyl
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
IL11883696A
Other versions
IL118836A (en
Original Assignee
Teva Pharmaceutical Ltd
Technion Res & Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Ltd, Technion Res & Dev Foundation filed Critical Teva Pharmaceutical Ltd
Priority to IL11883696A priority Critical patent/IL118836A/en
Publication of IL118836D0 publication Critical patent/IL118836D0/en
Publication of IL118836A publication Critical patent/IL118836A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/878Geriatrics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/878Geriatrics
    • Y10S514/879Senility
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/903Multiple sclerosis
IL11883696A 1996-07-11 1996-07-11 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan IL118836A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL11883696A IL118836A (en) 1996-07-11 1996-07-11 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
IL11883696A IL118836A (en) 1996-07-11 1996-07-11 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
CA002260037A CA2260037C (en) 1996-07-11 1997-06-20 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
AT97927353T AT328590T (en) 1996-07-11 1997-06-20 Pharmaceutical compositions containing S - (-) -N-propargyl-1-aminoindan
HU9904525A HU226961B1 (en) 1996-07-11 1997-06-20 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan
JP50580698A JP4368421B2 (en) 1996-07-11 1997-06-20 S - (-) - n- propargyl-1-pharmaceutical composition comprising a aminoindan
DE69736066T DE69736066T2 (en) 1996-07-11 1997-06-20 Pharmaceutical compositions containing S - (-) - N-propargyl-1-aminoindan
AU31880/97A AU3188097A (en) 1996-07-11 1997-06-20 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan
PCT/IL1997/000205 WO1998002152A1 (en) 1996-07-11 1997-06-20 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan
CNB971971994A CN1149985C (en) 1996-07-11 1997-06-20 Pharmaceutical compositions comprising S-(-)-N-Propargyl-1-amino indan
DE69736066A DE69736066D1 (en) 1996-07-11 1997-06-20 Pharmaceutical compositions containing S - (-) - N-propargyl-1-aminoindan
EP97927353A EP0929298B1 (en) 1996-07-11 1997-06-20 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan
NO19990088A NO326052B1 (en) 1996-07-11 1999-01-08 Use of S - (-) - N-propargyl-1-aminoindamin or a pharmaceutically acceptable salt thereof for the manufacture of a medicament (a) for the treatment of neurotrauma or (b) for improving memory in a post-CHI patient.
US09/228,153 US6277886B1 (en) 1996-07-11 1999-01-11 Pharmaceutical compositions comprising S-(−)-N-propargyl-1-aminoindan

Publications (2)

Publication Number Publication Date
IL118836D0 true IL118836D0 (en) 1996-10-31
IL118836A IL118836A (en) 2001-01-11

Family

ID=11069065

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11883696A IL118836A (en) 1996-07-11 1996-07-11 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan

Country Status (12)

Country Link
US (1) US6277886B1 (en)
EP (1) EP0929298B1 (en)
JP (1) JP4368421B2 (en)
CN (1) CN1149985C (en)
AT (1) AT328590T (en)
AU (1) AU3188097A (en)
CA (1) CA2260037C (en)
DE (2) DE69736066D1 (en)
HU (1) HU226961B1 (en)
IL (1) IL118836A (en)
NO (1) NO326052B1 (en)
WO (1) WO1998002152A1 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
WO2002069977A1 (en) 2001-03-01 2002-09-12 Hollis-Eden Pharmaceuticals, Inc. Use of certain steroids for treatment of blood cell deficiencies
EP2298315A1 (en) 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
AU2003282337B2 (en) * 2002-11-07 2009-07-16 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
DK1567152T3 (en) 2002-11-15 2013-10-07 Teva Pharma Use of rasagiline with riluzole for the treatment of amyotrophic lateral sclerosis
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
EP2433626B1 (en) * 2003-11-25 2015-11-04 Technion Research & Development Foundation Ltd. Compositions and methods for treatment of cardiovascular disorders and diseases
JP2005232148A (en) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd Use of propargylamine as neuroprotective agent
JP2008507586A (en) * 2004-07-26 2008-03-13 テバ ファーマシューティカル インダストリーズ リミティド Including Rasagurin, pharmaceutical dosage
US20060025446A1 (en) * 2004-07-27 2006-02-02 Jeffrey Sterling Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
EP1807118B8 (en) 2004-09-29 2014-04-23 Harbor Therapeutics, Inc. Steroid analogs and characterization and treatment methods
RS52867B (en) * 2005-02-17 2013-12-31 Teva Pharmaceutical Industries Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
JP5738509B2 (en) 2005-02-23 2015-06-24 テバ ファーマシューティカル インダストリーズ リミティド Rasagiline formulation content uniformity is improved
US8263655B2 (en) 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
US7491847B2 (en) 2005-11-17 2009-02-17 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
JP2009518433A (en) 2005-12-09 2009-05-07 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム Use of low-dose ladostigil for neuroprotection
US8809310B2 (en) 2006-02-21 2014-08-19 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
JP5769923B2 (en) 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド Use of rasagiline for the treatment of Restless Legs Syndrome
EP1892233A1 (en) * 2006-08-18 2008-02-27 Ratiopharm GmbH New salts of the active component rasagiline
CN101600346B (en) * 2006-12-14 2013-08-21 泰华制药工业有限公司 Tannate salt of rasagiline
CN101557706B (en) * 2006-12-14 2013-08-07 泰华制药工业有限公司 Crystalline solid rasagiline base
EP1987816A1 (en) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate of a rasagiline salt with a water-soluble inactive ingredient
JP2010538067A (en) * 2007-09-05 2010-12-09 テバ ファーマシューティカル インダストリーズ リミティド A method of treatment of glaucoma to use the rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
BRPI0905680A2 (en) * 2008-01-11 2015-07-07 Teva Pharma "Pharmaceutical composition a pharmaceutical composition"
US20110027354A1 (en) * 2008-04-01 2011-02-03 Kim Hyoung-Chun Anti-parkinsonian compounds
EP2285214B1 (en) * 2008-06-10 2012-05-16 Teva Pharmaceutical Industries Ltd. Rasagiline soft gelatin capsules
BRPI0909894A2 (en) * 2008-06-13 2015-07-28 Teva Pharma "Speed ​​reduction method of progression of Parkinson's disease in a patient with Parkinson's disease at an early stage speed reduction method of progression of Parkinson's disease, delay method of the need for symptomatic antiparkinsonian therapy in a bad patient Parkinson's disease at an early stage, the risk of a patient reduction method with Parkinson's disease that requires anti-Parkinson therapy, reducing the functional decline method of a patient with Parkinson's disease at an early stage, reducing the functional decline method in a patient with Parkinson's disease, a method of treating a patient exhibiting early signs of Parkinson's disease, fatigue reduction method in a patient with Parkinson's disease at an early stage method of reducing clinical progression rate and treatment of bad symptoms Parkinson's disease in a patient with Parkinson's disease, rasagiline or a pharmaceutically acceptable salt of rasagiline pharmaceutical composition.
AU2009260733B2 (en) * 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
BRPI0909997A2 (en) * 2008-06-19 2015-10-27 Teva Pharma R (+) - N-propargyl-1-aminoindan, pharmaceutical composition, r-drying process (+) - Solid N-propargyl-1-aminoindan, for preparing a pharmaceutical composition process, the process of producing a validated batch a drug product containing crystalline R (+) - n-propargyl-1-aminoindan and at least one pharmaceutically acceptable carrier for distribution and prudução process for R (+) - n-propargyl-1-aminoindan
US20100189788A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
EP2451771B1 (en) 2009-07-09 2014-06-18 Ratiopharm GmbH Salts of rasagiline and pharmaceutical preparations thereof
US9943489B2 (en) 2010-02-03 2018-04-17 Pharmatwob Ltd. Extended release formulations of rasagiline and uses thereof
EP2603212A4 (en) 2010-07-27 2014-01-08 Teva Pharma Use of rasagiline for the treatment of olfactory dysfunction
WO2012015946A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Dispersion of rasagiline citrate
AU2012323349A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-formyl-propargyl-aminoindan
WO2013055689A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-methyl-propargyl-aminoindan
CA2882072A1 (en) 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulations of rasagiline
CN104177610A (en) * 2013-05-27 2014-12-03 韩文毅 Non-linear polymer, and preparation and application thereof
CN104177611A (en) * 2013-05-27 2014-12-03 韩文毅 Nonlinear polymer and preparation and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL112819A (en) * 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
DE69535315D1 (en) * 1994-01-10 2007-01-11 Teva Pharma 1-aminoindanderivate and compositions thereof
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan

Also Published As

Publication number Publication date
IL118836A (en) 2001-01-11
HU9904525A2 (en) 2000-11-28
NO326052B1 (en) 2008-09-08
CA2260037C (en) 2007-01-23
AT328590T (en) 2006-06-15
CN1227486A (en) 1999-09-01
JP2000514453A (en) 2000-10-31
AU3188097A (en) 1998-02-09
DE69736066D1 (en) 2006-07-20
DE69736066T2 (en) 2006-12-28
EP0929298B1 (en) 2006-06-07
NO990088L (en) 1999-03-10
CN1149985C (en) 2004-05-19
EP0929298A1 (en) 1999-07-21
US6277886B1 (en) 2001-08-21
HU226961B1 (en) 2010-03-29
HU9904525A3 (en) 2000-12-28
NO990088D0 (en) 1999-01-08
JP4368421B2 (en) 2009-11-18
CA2260037A1 (en) 1998-01-22
WO1998002152A1 (en) 1998-01-22

Similar Documents

Publication Publication Date Title
EG24435A (en) Novel pharmaceutical composition
GB2298789B (en) Pharmaceutical compositions
SK79496A3 (en) Pharmaceutical composition
IL128765D0 (en) Pharmaceutical compositions containing isoflavones
IL133293D0 (en) Pharmaceutical compositions comprising cyclodextrins
HK1019544A1 (en) Composition
HU9903759A3 (en) Abtimicrobial compositions
IL127611D0 (en) Aqueous-based pharmaceutical composition
PL175210B1 (en) New pharmaceutical compositions
EP1017379A4 (en) Therapeutic compositions
EP0957903A4 (en) Pharmaceutical compositions and methods
EP1073439A4 (en) Pharmaceutical composition
ZA9705062B (en) Skinwash composition
SK11702000A3 (en) Pharmaceutical composition
OA11040A (en) Pharmaceutical formulations
AU3924895A (en) Pharmaceutical compositions
GB9408117D0 (en) Pharmaceutical formulations
AU3553097A (en) Pharmaceutical composition
AU3188097A (en) Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan
HRP970100A2 (en) Pharmaceutical composition for immunomodulation
AU3845195A (en) Pharmaceutical compositions
CY2603B2 (en) Pharmaceutical compositions
GB9517062D0 (en) Pharmaceutical compositions
ZA9509469B (en) Pharmaceutical composition
ZA9703653B (en) Pharmaceutical compositions.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees
NE Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired